Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis

Background: Survival rates for anaplastic thyroid cancer (ATC) have not improved in the past four decades; however, preliminary clinical data indicate that lenvatinib may provide efficacy benefits for patients with ATC. This real-world study aimed to define the potential role of lenvatinib in ATC by...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Soo Young, Kim, Seok-Mo, Kim, Jun Won, Lee, Ik Jae, Jeon, Tae Joo, Chang, Hojin, Kim, Bup-Woo, Lee, Yong Sang, Chang, Hang-Seok, Park, Cheong Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492269/
https://www.ncbi.nlm.nih.gov/pubmed/32982983
http://dx.doi.org/10.3389/fendo.2020.00599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492269/
https://www.ncbi.nlm.nih.gov/pubmed/32982983
http://dx.doi.org/10.3389/fendo.2020.00599

Ejemplares similares